PTHLH and Familial prostate cancer: Harada and collaborators, who had identified protein fragments suitable for immunotherapy of HLA-A24+ and HLA-A2+ prostate cancer patients [54,55], in 2005 reported that C-terminal domains of PTHrP could be successfully used also to induce in vitro peptide-specific and cancer-reactive cytotoxic T lymphocytes from blood cells of gastric, colon and cervical cancer-affected patients, which could allow the design of specific vaccines [56].